IQVIA Holdings (IQV) is back in focus after expanding its collaboration with Kexing Biopharm to use AI-enabled clinical trial tools across a global, multi product biosimilar program, drawing fresh attention to the stock.

The stock’s 1 day share price return declined 1.53% to $172.38, extending a 7 day share price pullback of 2.32%. However, the 1 year total shareholder return of 21.55% contrasts with weaker multi year outcomes and indicates that momentum has recently been rebuilding from a lower base.

If AI in clinical trials is on your radar, it could be a good time to broaden your watchlist with other healthcare focused AI opportunities via the 33 healthcare AI stocks.

With IQVIA trading at $172.38, alongside an indicated intrinsic discount of about 45% and a 1 year total return of 21.55%, is the stock still underappreciated, or is the market already pricing in years of future growth?

Most Popular Narrative: 25.6% Undervalued

IQVIA’s most followed narrative points to a fair value of $231.60 against the last close of $172.38, framing a sizeable potential valuation gap built on earnings and cash flow assumptions.

Accelerated adoption of AI-driven analytics and data solutions, supported by strong client demand and high-profile industry partnerships like NVIDIA, positions IQVIA for improved operational efficiency, faster project execution, and differentiation, which should support future revenue growth and eventual margin expansion as AI capabilities scale.

Curious how this narrative gets to that higher fair value? It leans on steady revenue gains, firmer margins, and a future earnings profile that commands a richer multiple. The exact mix of growth rates, profitability and discounting is where the real story sits.

Result: Fair Value of $231.60 (UNDERVALUED)

However, pressure on CRO pricing and high leverage could squeeze margins and flexibility, especially if clients slow project decisions or push harder on contract terms.

Next Steps

Given the mix of optimism around AI tools and concern about leverage and pricing, it helps to review the data yourself and act quickly while this story is still taking shape. You can start with the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If IQVIA has your attention, do not stop here. Use the Simply Wall St Screener to quickly surface fresh stock ideas before other investors catch on.

• Target potential value opportunities by scanning for companies that look mispriced relative to fundamentals through the 47 high quality undervalued stocks.
• Strengthen your defensives by focusing on companies with sturdy finances using the solid balance sheet and fundamentals stocks screener (45 results).
• Get ahead of the crowd by searching for lesser known opportunities with solid metrics in the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.